Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31No description of principal activityfalse2023-04-01true00false 11237871 2023-04-01 2024-03-31 11237871 2022-04-01 2023-03-31 11237871 2024-03-31 11237871 2023-03-31 11237871 c:Director5 2023-04-01 2024-03-31 11237871 c:EntityHasNeverTraded 2023-04-01 2024-03-31 11237871 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 11237871 c:FullAccounts 2023-04-01 2024-03-31 11237871 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 11237871 c:Micro-entities 2023-04-01 2024-03-31 11237871 d:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 11237871










MATOKE PHARMACEUTICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2024

 
MATOKE PHARMACEUTICAL LIMITED
REGISTERED NUMBER: 11237871

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
£
£


Current assets
1
1

Net current assets
 
 
1
 
 
1

Total assets less current liabilities
1
1


Net assets
1
1



Capital and reserves
1
1


Notes


General information

Matoke Pharmaceutical Limited is a private company, limited by shares, registered in England and Wales. The registered office is 2 Michaels Court, Hanney Road, Southmoor, Oxfordshire, OX13 5HR.

The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 November 2024.




................................................
William E A Wijnberg
Director

Page 1